Skip to content
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
BioTechGrid BioTechGrid
  • Home
  • Biotechnology
  • Medical Technology
  • Research
  • Genetics
  • Press Releases
    • Business Wire
    • GlobeNewswire
    • PRNewswire
  • Contact
  • Home
  • Biotechnology
  • Boehringer adds $250M to value of Variant pact by expanding into cardiovascular disease

Boehringer adds $250M to value of Variant pact by expanding into cardiovascular disease

September 23, 2026Posted inBiotechnology

Boehringer Ingelheim has dived deeper into its collaboration with Variant Bio by expanding the collaboration to cover cardiovascular disease to the tune of $250 million.

Post navigation

Previous Post
ai-powered-image-analysis-delivers-precise-rockfill-characterization-for-dam-safety AI-Powered Image Analysis Delivers Precise Rockfill Characterization for Dam Safety
Next Post
Immunovant ends cutaneous lupus program after phase 2 flop

Recent Posts

  • Four-Year-Old Receives China’s Youngest Documented Leadless Pacemaker Implantation
  • Questionnaire Layout Associated With Response Patterns in Orthopaedic Patient Surveys
  • Lower Vitamin D and Magnesium Levels Track Degenerative Temporomandibular Disorders
  • Immune Microenvironment Breakdown at Neuromuscular Junctions Drives Early Sarcopenia
  • LoRA-BERT Accurately Predicts Long Non-Coding RNAs Even From Partial Transcripts

Archives

  • November 2026
  • October 2026
  • September 2026
  • August 2026
  • July 2026
  • September 2024
  • August 2024
  • March 2024
  • September 2023

Privacy Policy    Terms

Scroll to Top